Current developments and prospects on human metapneumovirus vaccines

Area of Science:

• Virology
• Vaccinology
• Biotechnology

Background:

• Human metapneumovirus (hMPV) is a primary cause of acute respiratory infections (ARI), particularly in vulnerable populations like children, the elderly, and immunocompromised individuals.
• Despite its significance, no licensed vaccines are currently available to prevent hMPV infections.

Purpose of the Study:

• To review the progress of vaccine development against hMPV since its discovery in 2001.
• To analyze outcomes from preclinical studies (cell cultures, animal models) and the sole clinical trial candidate.
• To discuss limitations of existing vaccine candidates and explore the potential of plant-based vaccine technologies.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies on hMPV vaccine development.
• Analysis of data from cell culture and animal model studies.
• Evaluation of the progress and outcomes of the only hMPV vaccine candidate that entered clinical trials.
• Exploration of molecular farming and plant-based vaccine approaches.

Main Results:

• Multiple hMPV vaccine candidates are in development, with some showing promise for clinical progression.
• Preclinical studies have provided valuable insights into potential vaccine strategies.
• The review identifies limitations in current vaccine candidates, highlighting the need for further innovation.

Conclusions:

• Several hMPV vaccine candidates are advancing, offering hope for future prevention of respiratory infections.
• Molecular farming presents a promising avenue for developing novel, advantageous vaccines against hMPV.
• Continued research and development are crucial to combat hMPV effectively.